Safer down syndrome test could replace Needle-Based procedure

NCT ID NCT02127515

Completed Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compared a simple blood test (noninvasive prenatal testing, or NIPT) with the standard invasive procedure (amniocentesis or chorionic villus sampling) for detecting Down syndrome in over 2,100 pregnant women at high risk. The goal was to see if NIPT could reduce miscarriages while still accurately identifying cases. Women were randomly assigned to either the blood test or the invasive test, and researchers tracked miscarriage rates, accuracy, and costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, NIPT could become a safer, noninvasive option for prenatal Down syndrome screening, reducing the need for invasive tests and their associated miscarriage risk.
What could go wrong: This trial is completed but results are not yet widely implemented. NIPT may have false positives or negatives, and it is not a diagnostic test—only a screening tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DOWN SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Abortion, Spontaneous Down syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DOWN SYNDROME

Contacts and locations

Locations

Hôpital Necker- Enfants Malades

Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.